{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:36:24Z","timestamp":1790289384643,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":40,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010155.pub2","type":"reference-entry","created":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T13:53:26Z","timestamp":1371045206000},"source":"Crossref","is-referenced-by-count":8,"title":["Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease"],"prefix":"10.1002","author":[{"given":"Esther J","family":"van Zuuren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbys","family":"Fedorowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,12]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD010155.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD010155.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"Abstract no: 23","DOI":"10.1182\/blood.V106.11.2340.2340","article-title":"Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia","volume":"106","author":"Qari","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010155.pub2-BIB3|cit3","unstructured":"NCT01419977 Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo www.clinicaltrials.gov\/show\/NCT01419977"},{"issue":"1","key":"10.1002\/14651858.CD010155.pub2-BIB4|cit4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006957","article-title":"Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease","author":"Al Hajeri","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010155.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"e29786","DOI":"10.1371\/journal.pone.0029786","article-title":"Association of coagulation activation with clinical complications in sickle cell disease","volume":"7","author":"Ataga","year":"2012","journal-title":"Plos One"},{"issue":"3","key":"10.1002\/14651858.CD010155.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/blood-2006-11-057604","article-title":"Sickle cell trait and the risk of venous thromboembolism among blacks","volume":"110","author":"Austin","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD010155.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"620.e1","DOI":"10.1016\/j.ajog.2009.01.038","article-title":"Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women","volume":"200","author":"Austin","year":"2009","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"1","key":"10.1002\/14651858.CD010155.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21550","article-title":"Definitions of the phenotypic manifestations of sickle cell disease","volume":"85","author":"Ballas","year":"2010","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD010155.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"949535","DOI":"10.1100\/2012\/949535","article-title":"Beyond the definitions of the phenotypic complications of sickle cell disease: An update on management","volume":"2012","author":"Ballas","year":"2012","journal-title":"The Scientific World Journal"},{"key":"10.1002\/14651858.CD010155.pub2-BIB10|cit10","unstructured":"Ballas SK Sickle cell anemia http:\/\/pier.acponline.org\/physicians\/diseases\/d905\/d905.html 1 93"},{"issue":"7572","key":"10.1002\/14651858.CD010155.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD010155.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2010-02-268193","article-title":"Pulmonary hypertension and nitric oxide depletion in sickle cell disease","volume":"116","author":"Bunn","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD010155.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.avsg.2006.07.003","article-title":"Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis","volume":"21","author":"Carr","year":"2007","journal-title":"Annals of Vascular Surgery"},{"issue":"2","key":"10.1002\/14651858.CD010155.pub2-BIB14|cit14","article-title":"Pneumococcal vaccines for sickle cell disease","author":"Davies","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010155.pub2-BIB15|cit15","first-page":"e2009024","article-title":"Pathophisiology of sickle cell disease and new drugs for the treatment","volume":"1","author":"Franceschi","year":"2009","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD010155.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-0031-1273087","article-title":"Thrombosis and sickle cell disease","volume":"37","author":"Franceschi","year":"2011","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1002\/14651858.CD010155.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"a1397","DOI":"10.1136\/bmj.a1397","article-title":"Management of sickle cell disease","volume":"337","author":"Montalembert","year":"2008","journal-title":"BMJ"},{"issue":"13","key":"10.1002\/14651858.CD010155.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2011.10.900","article-title":"Cardiovascular abnormalities in sickle cell disease","volume":"59","author":"Gladwin","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD010155.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ajh.22271","article-title":"Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications","volume":"87","author":"Goldsmith","year":"2012","journal-title":"American Journal of Hematology"},{"issue":"7414","key":"10.1002\/14651858.CD010155.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010155.pub2-BIB21|cit21","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011] The Cochrane Collaboration, 2011. Available from\u00a0www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010155.pub2-BIB22|cit22","unstructured":"Sterne JAC Egger M Moher D on behalf of the Cochrane Bias Methods Group Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011] The Cochrane Collaboration, 2011. Available from\u00a0www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010155.pub2-BIB23|cit23","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org\u00a0"},{"key":"10.1002\/14651858.CD010155.pub2-BIB24|cit24","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the CSMG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD010155.pub2-BIB25|cit25","first-page":"211","article-title":"Acute chest syndrome and other pulmonary manifestations of sickle cell disease","volume":"18","author":"Hirani","year":"2011","journal-title":"Journal of Clinical Outcome Management"},{"issue":"1","key":"10.1002\/14651858.CD010155.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V79.1.1.1","article-title":"Low molecular weight heparin","volume":"79","author":"Hirsh","year":"1992","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010155.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119 Suppl 1","author":"Hirsh","year":"2001","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD010155.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/11203710-000000000-00000","article-title":"Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis","volume":"70","author":"Hoy","year":"2010","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD010155.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0268-960X(09)70004-9","article-title":"Recent advances in improving the management of sickle cell disease","volume":"23 Suppl 1","author":"Inati","year":"2009","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD010155.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.3109\/03630260903347682","article-title":"Current understanding in the management of sickle cell disease","volume":"33 Suppl 1","author":"Inati","year":"2009","journal-title":"Hemoglobin"},{"issue":"3","key":"10.1002\/14651858.CD010155.pub2-BIB31|cit31","first-page":"13","article-title":"A comparative study of pain measurement scales in acute burn patients","volume":"35","author":"Jaywant","year":"2003","journal-title":"Indian Journal of Occupational Therapy"},{"key":"10.1002\/14651858.CD010155.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/asheducation-2010.1.418","article-title":"Sickle-cell trait: novel clinical significance","volume":"2010","author":"Key","year":"2010","journal-title":"Hematology\/ the Education Program of the American Society of Hematology"},{"issue":"7","key":"10.1002\/14651858.CD010155.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0091270003254793","article-title":"Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects","volume":"43","author":"Mousa","year":"2003","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010155.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/1076029609352661","article-title":"Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion","volume":"16","author":"Mousa","year":"2010","journal-title":"Clinical and Applied Thrombosis\/Haemostasis"},{"issue":"9757","key":"10.1002\/14651858.CD010155.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010155.pub2-BIB36|cit36","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"5","key":"10.1002\/14651858.CD010155.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"13","key":"10.1002\/14651858.CD010155.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199904013401307","article-title":"Management of sickle cell disease","volume":"340","author":"Steinberg","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010155.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"ITC31","DOI":"10.7326\/0003-4819-155-5-201109060-01003","article-title":"In the Clinic. Sickle cell disease","volume":"155","author":"Steinberg","year":"2011","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010155.pub2-BIB40|cit40","unstructured":"World Health Organization Sickle-cell anaemia. Report A59\/9. Provisional agenda item 11.4. 59th World Health Assembly https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA59\/A59_9-en.pdf"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010155.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T00:00:00Z","timestamp":1450396800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010155.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T08:53:13Z","timestamp":1715503993000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010155.pub2"}},"subtitle":[],"editor":[{"given":"Esther J","family":"van Zuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,12]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010155.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD010155.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2013,6,12]]}}}